Introduction：Basic information about CAS 122957-06-6|Modipafant, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Modipafant |
|---|
| CAS Number | 122957-06-6 | Molecular Weight | 605.08500 |
|---|
| Density | 1.34g/cm3 | Boiling Point | / |
|---|
| Molecular Formula | C34H29ClN6O3 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | ethyl (4R)-4-(2-chlorophenyl)-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyridin-1-yl)phenyl]-5-(pyridin-2-ylcarbamoyl)-1,4-dihydropyridine-3-carboxylate |
|---|
| Synonym | More Synonyms |
|---|
Modipafant BiologicalActivity
| Description | Modipafant (UK-80067), the (+)-enantiomer of UK-74505, is a potent, orally active, and selective platelet-activating factor (PAF) antagonist. Modipafant exhibits approximately double the intrinsic potency of UK-74505[1][2]. |
|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Inflammation/Immunology |
|---|
| In Vitro | when preincubated with rabbit platelets, the potency of antagonizing PAF induced aggregation increased markedly when preincubation time with Modipafant was increased from 2 min (IC50=5.6 nM) to 60 min (IC50=0.34 nM)[2]. |
|---|
| References | [1]. Kuitert LM, et al. Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. Am J Respir Crit Care Med. 1995;151(5):1331-1335. [2]. Jezequel SG, et al, a new PAF antagonist: pharmacokinetics and disposition in rat, dog and man. Xenobiotica. 1996;26(9):963-975. |
|---|
Chemical & Physical Properties
| Density | 1.34g/cm3 |
|---|
| Molecular Formula | C34H29ClN6O3 |
|---|
| Molecular Weight | 605.08500 |
|---|
| Exact Mass | 604.19900 |
|---|
| PSA | 111.03000 |
|---|
| LogP | 6.75300 |
|---|
| InChIKey | ODRYSCQFUGFOSU-SSEXGKCCSA-N |
|---|
| SMILES | CCOC(=O)C1=C(c2ccc(-n3c(C)nc4cnccc43)cc2)NC(C)=C(C(=O)Nc2ccccn2)C1c1ccccc1Cl |
|---|
Synonyms
| Modipafant |
| QCR-95 |
| UNII-1DMI0E5023 |
